Skip to main content Accessibility help
  • Print publication year: 2006
  • Online publication date: February 2010

17 - The rational use of blood and its components in obstetrical and gynecological bleeding complications

Goodnough, L. T., Brecher, M. E., Kanter, M. H., et al. Transfusion medicine. First of two parts – blood transfusion. N. Engl. J. Med., 1999; 340(6): 438–47.
Bausch, M. Blood safety in the new millennium. In Stramer, S., ed., American Association of Blood Banks. Bethesda, MD: 2001; Closing the windows on viral transmission by blood transfusion. pp. 33–54.
Busch, M. P., Kleinman, S. H., Jackson, B., et al. Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion, 2000; 40(2): 143–59.
Roth, W. K., Weber, M., Seifried, E.Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting. Lancet, 1999; 353(9150): 359–63.
Kuhns, M., McNamara, A., Peterson, B., et al. Detection of hepatitis B seroconversion by highly sensitive assays for surface antigen and HBV DNA (abstract). Transfusion, 1998; 3(Suppl.): 91S.
Peddada, L., Heldebrant, C., Smith, R., et al. HBV viremia preceding HbsAg positivity: Implications for minipool (MP) and individual donation (ID) HBV nucleic acid testing (NAT) (abstract). Transfusion, 2000; 40(Suppl.): 14–15S.
Stramer, S. L.Nucleic acid testing for transfusion-transmissible agents. Curr. Opin. Hematol., 2000; 7(6): 387–91.
Kleinman, S. H., Busch, M. P.The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract. Res. Clin. Haematol., 2000; 13(4): 631–49.
Saldanha, J.Validation and standardisation of nucleic acid amplification technology (NAT) assays for the detection of viral contamination of blood and blood products. J. Clin. Virol., 2001; 20(1–2): 7–13.
Holmes, H., Davis, C., Heath, A., et al. An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J. Virol. Methods, 2001; 92(2): 141–50.
Downes, K. A., Yomtovian, R.Advances in pretransfusion infectious disease testing: ensuring the safety of transfusion therapy. Clin. Lab. Med., 2002; 22(2): 475–90.
Dodd, R. Y.Emerging infections, transfusion safety, and epidemiology. N. Engl. J. Med., 2003; 349(13): 1205–6.
Goodman, C., Chan, S., Collins, P., et al. Ensuring blood safety and availability in the US: technological advances, costs, and challenges to payment – final report. Transfusion, 2003; 43(8 Suppl.): 3S–46S.
Dodd, R. Y., Leiby, D. A.Emerging infectious threats to the blood supply. Annu. Rev. Med., 2004; 55: 191–207.
Pealer, L. N., Marfin, A. A., Petersen, L. R., et al. Transmission of West Nile virus through blood transfusion in the United States in 2002. N. Engl. J. Med., 2003; 349(13): 1236–45.
Mather, T., Takeda, T., Tassello, J., et al. West Nile virus in blood: stability, distribution, and susceptibility to PEN110 inactivation. Transfusion, 2003; 43(8): 1029–37.
Harrington, T., Kuehnert, M. J., Kamel, H., et al. West Nile virus infection transmitted by blood transfusion. Transfusion, 2003; 43(8): 1018–22.
Biggerstaff, B. J., Petersen, L. R.Estimated risk of transmission of the West Nile virus through blood transfusion in the US, 2002. Transfusion, 2003; 43(8): 1007–17.
Biggerstaff, B. J., Petersen, L. R.Estimated risk of West Nile virus transmission through blood transfusion during an epidemic in Queens, New York City. Transfusion, 2002; 42(8): 1019–26.
Centers for Disease Control and Prevention CfDCaP. Detection of West Nile virus in blood donations – United States. MMRR, 2003; 52(32): 769–72.
Yap, P. L., Leaver, H. A., Gillon, J.Prions: properties, occurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang, 1998; 74 (Suppl. 2): 131–4.
Brown, P., Rohwer, R. G., Dunstan, B. C., et al. The distribution of infectivity in blood components and plasma derivatives in experimental models of transmissible spongiform encephalopathy. Transfusion, 1998; 38(9): 810–16.
Linden, J. V.Errors in transfusion medicine. Scope of the problem. Arch. Pathol. Lab. Med., 1999; 123(7): 563–5.
Myhre, B. A.Fatalities from blood transfusion. JAMA, 1980; 244(12): 1333–5.
Dzik, W. H., Corwin, H., Goodnough, L. T., et al. Patient safety and blood transfusion: new solutions. Transfus. Med. Rev., 2003; 17(3): 169–80.
Voak, D., Chapman, J. F., Phillips, P.Quality of transfusion practice beyond the blood transfusion laboratory is essential to prevent ABO-incompatible death. Transfus. Med., 2000; 10(2): 95–6.
Janatpour, K., Holland, P. V.Noninfectious serious hazards of transfusion. Curr. Hematol. Rep., 2002; 1(2): 149–55.
Domen, R. E., Hoeltge, G. A.Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch. Pathol. Lab. Med., 2003; 127(3): 316–20.
Silliman, C. C.Transfusion-related acute lung injury. Transfus. Med. Rev., 1999; 13(3): 177–86.
Kopko, P. M., Marshall, C. S., MacKenzie, M. R., et al. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA, 2002; 287(15): 1968–71.
Perrotta, P. L., Snyder, E. L.Non-infectious complications of transfusion therapy. Blood. Rev., 2001; 15(2): 69–83.
Popovsky, M. A.Breathlessness and blood: a combustible combination. Vox Sang, 2002; 83 (Suppl. 1): 147–50.
Moroff, G., Luban, N. L.The irradiation of blood and blood components to prevent graft-versus-host disease: technical issues and guidelines. Transfus. Med. Rev., 1997; 11(1): 15–26.
Schroeder, M. L.Transfusion-associated graft-versus-host disease. Br. J. Haematol., 2002; 117(2): 275–87.
Wagner, F. F., Flegel, W. A.Transfusion-associated graft-versus-host disease: risk due to homozygous HLA haplotypes. Transfusion, 1995; 35(4): 284–91.
Shulman, I. A., Downes, K. A., Sazama, K., et al. Pretransfusion compatibility testing for red blood cell administration. Curr. Opin. Hematol., 2001; 8(6): 397–404.
Gorlin, J, ed. XXII edn. Standards for Blood Banks and Transfusion Services. Bethesda, MD: American Association of Blood Banks; 2003.
Blood component preparation, storage, shipping, and transportation. In American Association of Blood Banks Technical Manual. Bethesda, MD: AABB Press; 1999. p. 169.
Practice guidelines for blood component therapy: A report by the American Society of Anesthesiologists Task Force on Blood Component Therapy. Anesthesiology, 1996; 84(3): 732–47.
Laine, E., Steadman, R., Calhoun, L., et al. Comparison of RBCs and FFP with whole blood during liver transplant surgery. Transfusion, 2003; 43(3): 322–7.
Holme, S., Elfath, M. D., Whitley, P.Evaluation of in vivo and in vitro quality of apheresis-collected RBC stored for 42 days. Vox Sang, 1998; 75(3): 212–17.
Consensus conference. Perioperative red blood cell transfusion. JAMA, 1988; 260(18): 2700–3.
Consensus conference. Platelet transfusion therapy. JAMA, 1987; 257(13): 1777–80.
Schiffer, C. A., Anderson, K. C., Bennett, C. L., et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J. Clin. Oncol., 2001; 19(5): 1519–38.
Lozano, M., Cid, J.The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus. Med. Rev., 2003; 17(1): 57–68.
Menitove, J. E.Immunoprophylaxis for D− patients receiving platelet transfusions from D+ [correction of D−] donors?Transfusion, 2002; 42(2): 136–8.
Practice parameter for the use of fresh-frozen plasma, cryoprecipitate, and platelets. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force of the College of American Pathologists. JAMA, 1994; 271(10): 777–81.
Downes, K. A., Wilson, E., Yomtovian, R., et al. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion, 2001; 41(4): 570.
Kaul, V. V., Munoz, S. J.Coagulopathy of liver disease. Curr. Treat. Options. Gastroenterol., 2000; 3(6): 433–8.
Amitrano, L., Guardascione, M. A., Brancaccio, V., et al. Coagulation disorders in liver disease. Semin. Liver Dis., 2002; 22(1): 83–96.
Dhar, P., Abramovitz, S., DiMichele, D., et al. Management of pregnancy in a patient with severe haemophilia A. Br. J. Anaesth., 2003; 91(3): 432–5.
Lao, T. T., Lewinsky, R. M., Ohlsson, A., et al. Factor XII deficiency and pregnancy. Obstet. Gynecol., 1991; 78(3 Pt 2): 491–3.
Schved, J. F., Gris, J. C., Neveu, S., et al. Variations of factor XII level during pregnancy in a woman with Hageman factor deficiency. Thromb. Haemost., 1988; 60(3): 526–7.
DiPaola, J., Nugent, D., Young, G.Current therapy for rare factor deficiencies. Haemophilia, 2001; 7 (Suppl. 1): 16–22.
Bianco, C.Choice of human plasma preparations for transfusion. Transfus. Med. Rev., 1999; 13(2): 84–8.
Consensus conference. Fresh-frozen plasma. Indications and risks. JAMA, 1985; 253(4): 551–3.
Downes, K., Sarode, R.Massive blood transfusion. Indian J. Pediatr., 2001; 68(2): 145–9.
Kobayashi, T., Asahina, T., Maehara, K., et al. Congenital afibrinogenemia with successful delivery. Gynecol. Obstet. Invest., 1996; 42(1): 66–9.
Thompson, H. W., Touris, S., Giambartolomei, S., et al. Treatment of congenital afibrinogenemia with cryoprecipitate collected through a plasmapheresis program using dedicated donors. J. Clin. Apheresis, 1998; 13(4): 143–5.
Deering, S. H., Landy, H. J., Tchabo, N., et al. Hypodysfibrinogenemia during pregnancy, labor, and delivery. Obstet. Gynecol., 2003; 101(5 Pt 2): 1092–4.
Iwaki, T., Sandoval-Cooper, M. J., Paiva, M., et al. Fibrinogen stabilizes placental–maternal attachment during embryonic development in the mouse. Am. J. Pathol., 2002; 160(3): 1021–34.
Ness, P. M., Budzynski, A. Z., Olexa, S. A., et al. Congenital hypofibrinogenemia and recurrent placental abruption. Obstet. Gynecol., 1983; 61(4): 519–23.
Inbal, A., Muszbek, L.Coagulation factor deficiencies and pregnancy loss. Semin. Thromb. Hemost., 2003; 29(2): 171–4.
Ichinose, A., Izumi, T., Hashiguchi, T.The normal and abnormal genes of the a and b subunits in coagulation factor XIII. Semin. Thromb. Hemost., 1996; 22(5): 385–91.
Duckert, F.Documentation of the plasma factor XIII deficiency in man. Ann. NY Acad. Sci., 1972; 202: 190–9.
Lak, M., Peyvandi, F., Ali Sharifian, A., et al. Pattern of symptoms in 93 Iranian patients with severe factor XIII deficiency. J. Thromb. Haemost., 2003; 1(8): 1852–3.
Koseki-Kuno, S., Yamakawa, M., Dickneite, G., et al. Factor XIII A subunit-deficient mice developed severe uterine bleeding events and subsequent spontaneous miscarriages. Blood, 2003; 102(13): 4410–12.
Burrows, R. F., Ray, J. G., Burrows, E. A.Bleeding risk and reproductive capacity among patients with factor XIII deficiency: a case presentation and review of the literature. Obstet. Gynecol. Surv., 2000; 55(2): 103–8.
Boda, Z., Pfliegler, G., Muszbek, L., et al. Congenital factor XIII deficiency with multiple benign breast tumours and successful pregnancy with substitutive therapy. A case report. Haemostasis, 1989; 19(6): 348–52.
Janson, P. A., Jubelirer, S. J., Weinstein, M. J., et al. Treatment of the bleeding tendency in uremia with cryoprecipitate. N. Engl. J. Med., 1980; 303(23): 1318–22.
Remuzzi, G.Bleeding in renal failure. Lancet, 1988; 1(8596): 1205–8.
The Trial to Reduce Alloimmunization to Platelets (TRAP) Study Group. Leukocyte reduction and ultraviolet irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. N. Eng. J. Med., 1997; 337: 1861–9.
Seftel, M. D., Growe, G. H., Petraszko, T., et al. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood, 2004; 103(1): 333–9.
Aye, M. T., Palmer, D. S., Giulivi, A., et al. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion, 1995; 35(2): 117–24.
Jahr, J. S., Nesargi, S. B., Lewis, K., et al. Blood substitutes and oxygen therapeutics: an overview and current status. Am. J. Ther., 2002; 9(5): 437–43.
Levy, J. H.Hemoglobin-based oxygen-carrying solutions: close but still so far. Anesthesiology, 2000; 92(3): 639–41.
Vlahakes, G. J.Hemoglobin solutions come of age. Anesthesiology, 2000; 92(3): 637–8.
Winslow, R. M.New transfusion strategies: red cell substitutes. Annu. Rev. Med., 1999; 50: 337–53.
Widness, J. A., Clemons, G. K., Garcia, J. F., et al. Plasma immunoreactive erythropoietin in normal women studied sequentially during and after pregnancy. Am. J. Obstet. Gynecol., 1984; 149(6): 646–50.
Harstad, T. W., Mason, R. A., Cox, S. M.Serum erythropoietin quantitation in pregnancy using an enzyme-linked immunoassay. Am. J. Perinatol., 1992; 9(4): 233–5.
Widness, J. A., Sawyer, S. T., Schmidt, R. L., et al. Lack of maternal to fetal transfer of 125I-labelled erythropoietin in sheep. J. Dev. Physiol., 1991; 15(3): 139–43.
Koury, M. J., Bondurant, M. C., Graber, S. E., et al. Erythropoietin messenger RNA levels in developing mice and transfer of 125I-erythropoietin by the placenta. J. Clin. Invest., 1988; 82(1): 154–9.
Braga, J., Marques, R., Branco, A., et al. Maternal and perinatal implications of the use of human recombinant erythropoietin. Acta Obstet. Gynecol. Scand., 1996; 75(5): 449–53.
Goodnough, L. T.Erythropoietin therapy versus red cell transfusion. Curr. Opin. Hematol., 2001; 8(6): 405–10.
Harris, S. A., Payne, G. Jr., Putman, J. M.Erythropoietin treatment of erythropoietin-deficient anemia without renal disease during pregnancy. Obstet. Gynecol., 1996; 87(5 Pt 2): 812–14.
Hatzis, T., Cardamakis, E., Tsapanos, V., et al. The effects of recombinant human erythropoietin given immediately after delivery to women with anaemia. Curr. Med. Res. Opin., 2003; 19(4): 346–9.
Hou, S., Orlowski, J., Pahl, M., et al. Pregnancy in women with end-stage renal disease: treatment of anemia and premature labor. Am. J. Kidney Dis., 1993; 21(1): 16–22.
Szurkowski, M., Wiecek, A., Kokot, F., et al. Safety and efficiency of recombinant human erythropoietin treatment in anemic pregnant women with a kidney transplant. Nephron, 1994; 67(2): 242–3.
Yankowitz, J., Piraino, B., Laifer, S. A., et al. Erythropoietin in pregnancies complicated by severe anemia of renal failure. Obstet. Gynecol., 1992; 80(3 Pt 2): 485–8.
Smith, R.Applications of darbepoietin-alpha, a novel erythropoiesis-stimulating protein, in oncology. Curr. Opin. Hematol., 2002; 9(3): 228–33.
Smith, R. E. Jr., Jaiyesimi, I. A., Meza, L. A., et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br. J. Cancer, 2001; 84 (Suppl. 1): 24–30.
Glaspy, J., Jadeja, J. S., Justice, G., et al. A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy. Br. J. Cancer, 2001; 84 (Suppl. 1): 17–23.
Overbay, D. K., Manley, H. J.Darbepoetin-alpha: a review of the literature. Pharmacotherapy, 2002; 22(7): 889–97.
Joy, M. S.Darbepoetin alfa: a novel erythropoiesis-stimulating protein. Ann. Pharmacother., 2002; 36(7–8): 1183–92.
Fisher, J. W.Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (Maywood), 2003; 228(1): 1–14.
Dutton, R. P., Hess, J. R., Scalea, T. M.Recombinant factor VIIa for control of hemorrhage: early experience in critically ill trauma patients. J. Clin. Anesth., 2003; 15(3): 184–8.
Hedner, U., Ingerslev, J.Clinical use of recombinant FVIIa (rFVIIa). Transfus. Sci., 1998; 19(2): 163–76.
Eskandari, N., Feldman, N., Greenspoon, J. S.Factor VII deficiency in pregnancy treated with recombinant factor VIIa. Obstet. Gynecol., 2002; 99(5 Pt 2): 935–7.
Sherer, D. M., Lerner, R.Glanzmann's thrombasthenia in pregnancy: a case and review of the literature. Am. J. Perinatol., 1999; 16(6): 297–301.
Bell, J. A., Savidge, G. F.Glanzmann's thrombasthenia proposed optimal management during surgery and delivery. Clin. Appl. Thromb. Hemost., 2003; 9(2): 167–70.
Segal, S., Shemesh, I. Y., Blumenthal, R., et al. Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa). Arch. Gynecol. Obstet., 2003; 268(4): 266–7.
Sacks, D. A., Koppes, R. H.Caring for the female Jehovah's Witness: balancing medicine, ethics, and the First Amendment. Am. J. Obstet. Gynecol., 1994; 170(2): 452–5.
Gyamfi, C., Gyamfi, M. M., Berkowitz, R. L.Ethical and medicolegal considerations in the obstetric care of a Jehovah's Witness. Obstet. Gynecol., 2003; 102(1): 173–80.
Drew, N. C.The pregnant Jehovah's Witness. J. Med. Ethics, 1981; 7(3): 137–9.
Singla, A. K., Lapinski, R. H., Berkowitz, R. L., et al. Are women who are Jehovah's Witnesses at risk of maternal death?Am. J. Obstet. Gynecol., 2001; 185(4): 893–5.
Migden, D. R., Braen, G. R.The Jehovah's Witness blood refusal card: ethical and medicolegal considerations for emergency physicians. Acad. Emerg. Med., 1998; 5(8): 815–24.
Smoller, B. R., Kruskall, M. S.Phlebotomy for diagnostic laboratory tests in adults. Pattern of use and effect on transfusion requirements. N. Engl. J. Med., 1986; 314(19): 1233–5.
Lusher, J. M.Systemic causes of excessive uterine bleeding. Semin. Hematol., 1999; 36(3 Suppl. 4): 10–20.
Lops, V. R., Hunter, L. P., Dixon, L. R.Anemia in pregnancy. Am. Fam. Physician, 1995; 51(5): 1189–97.
Pahlavan, P., Nezhat, C.Hemorrhage in obstetrics and gynecology. Curr. Opin. Obstet. Gynecol., 2001; 13(4): 419–24.
Crane, S., Chun, B., Acker, D.Treatment of obstetrical hemorrhagic emergencies. Curr. Opin. Obstet. Gynecol., 1993; 5(5): 675–82.
Bonnar, J.Massive obstetric haemorrhage. Baillieres Best Pract. Res. Clin. Obstet. Gynaecol., 2000; 14(1): 1–18.
Broek, N. R., White, S. A., Ntonya, C., et al. Reproductive health in rural Malawi: a population-based survey. BJOG, 2003; 110(10): 902–8.
Pattinson, R. C., Buchmann, E., Mantel, G., et al. Can enquiries into severe acute maternal morbidity act as a surrogate for maternal death enquiries?BJOG, 2003; 110(10): 889–93.
Ronsmans, C., Etard, J. F., Walraven, G., et al. Maternal mortality and access to obstetric services in West Africa. Trop. Med. Int. Health, 2003; 8(10): 940–8.
Fenton, P. M., Whitty, C. J., Reynolds, F.Caesarean section in Malawi: prospective study of early maternal and perinatal mortality. BMJ, 2003; 327(7415): 587.
Adamu, Y. M., Salihu, H. M., Sathiakumar, N., et al. Maternal mortality in Northern Nigeria: a population-based study. Eur. J. Obstet. Gynecol. Reprod. Biol., 2003; 109(2): 153–9.
Okogbenin, S. A., Gharoro, E. P., Otoide, V. O., et al. Obstetric hysterectomy: fifteen years' experience in a Nigerian tertiary centre. J. Obstet. Gynaecol., 2003; 23(4): 356–9.
Chichakli, L. O., Atrash, H. K., MacKay, A. P., et al. Pregnancy-related mortality in the United States due to hemorrhage: 1979–1992. Obstet. Gynecol., 1999; 94(5 Pt 1): 721–5.
Chang, J., Elam-Evans, L. D., Berg, C. J., et al. Pregnancy-related mortality surveillance – United States, 1991–1999. MMWR Surveill. Summ., 2003; 52(2): 1–8.
Nagaya, K., Fetters, M. D., Ishikawa, M., et al. Causes of maternal mortality in Japan. JAMA, 2000; 283(20): 2661–7.
Chamberlain, G., Steer, P.ABC of labour care: obstetric emergencies. BMJ, 1999; 318(7194): 1342–5.
Stainsby, D., MacLennan, S., Hamilton, P. J.Management of massive blood loss: a template guideline. Br. J. Anaesth., 2000; 85(3): 487–91.
Shevell, T., Malone, F. D.Management of obstetric hemorrhage. Semin. Perinatol., 2003; 27(1): 86–104.
Schierhout, G., Roberts, I.Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ, 1998; 316(7136): 961–4.
Reviewers CIGA. Human albumin administration in critically ill patients: systematic review of randomized trials. Br. J. Med., 1998; 317: 235–40.
Chen, C. Y., Chen, C. P., Wang, K. G., et al. Factors implicated in the outcome of pregnancies complicated by acute respiratory failure. J. Reprod. Med., 2003; 48(8): 641–8.
Mechem, C. C., Knopp, R. K., Feldman, D.Painless abruptio placentae associated with disseminated intravascular coagulation and syncope. Ann. Emerg. Med., 1992; 21(7): 883–5.
Clark, S. L., Hankins, G. D., Dudley, D. A., et al. Amniotic fluid embolism: analysis of the national registry. Am. J. Obstet. Gynecol., 1995; 17(4 Pt 1): 1158–67; discussion, 1167–9.
Uszynski, M., Zekanowska, E., Uszynski, W., et al. Tissue factor (TF) and tissue factor pathway inhibitor (TFPI) in amniotic fluid and blood plasma: implications for the mechanism of amniotic fluid embolism. Eur. J. Obstet. Gynecol. Reprod. Biol., 2001; 95(2): 163–6.
Vichinsky, E. P.Current issues with blood transfusions in sickle cell disease. Semin. Hematol., 2001; 38(1, Suppl. 1): 14–22.
Anderson, R. R., Sosler, S. D., Kovach, J., et al. Delayed hemolytic transfusion reaction due to anti-Js(a) in an alloimmunized patient with a sickle cell syndrome. Am. J. Clin. Pathol., 1997; 108(6): 658–61.
Plante, L. A.Transfusion issues in a gravida with sickle cell disease. Obstet. Gynecol., 1998; 92(4 Pt 2): 712.
Eckman, J. R.Techniques for blood administration in sickle cell patients. Semin. Hematol., 2001; 38(1, Suppl. 1): 23–9.
Cunningham, F. G., Pritchard, J. A., Mason, R.Pregnancy and sickle cell hemoglobinopathies: results with and without prophylactic transfusions. Obstet. Gynecol., 1983; 62(4): 419–24.
Tahhan, H. R., Holbrook, C. T., Braddy, L. R., et al. Antigen-matched donor blood in the transfusion management of patients with sickle cell disease. Transfusion, 1994; 34(7): 562–9.
Win, N., Doughty, H., Telfer, P., et al. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion, 2001; 41(3): 323–8.